At Camillus, we are passionate about finding the next generation of pioneers with a founder's mentality and ownership mindset for sustained growth. We invest and partner with exciting companies at the frontiers of global healthcare, developing enabling technology and digital health.
EnPlusOne is enabling the future of RNA and RNA solutions. Its ezRNA™ synthesis platform is a revolutionary innovation that can incorporate a diverse array of nucleotide modifications. The promise of sustainably delivering therapeutic RNA at commercial scale has arrived. In addition to direct RNA synthesis, EnPlusOne's ezRNA™ platform supports a vast array of RNA solution applications
Relation discovers new biology to cure disease faster, transforming the traditional R&D model: because patients are waiting. Integral to this, Relation combines the power of active-graph machine learning and large-scale, high-quality data that describes disease biology to find better ways of targeting human pathology. We generate proprietary maps of disease in humans, leveraging human genetics, single-cell omics and perturbational data, so that these powerful models can be deployed at last. Relation’s platform sits in an integrated wet-lab, dry-lab, translational science loop, located in London.
Albotherm’s vision is to revolutionise the cooling industry by providing a low carbon solution to temperature regulation. Initially focussing on the farming sector, Albotherm’s temperature-responsive materials will maximise food productivity in commercial greenhouses and contribute to a more sustainable and resilient food system. The technology also has wide applications in the building sector, where low carbon cooling systems are in high demand. Albotherm’s advanced materials use polymer chemistry to automatically switch from transparent to opaque above an engineerable trigger air-temperature, reflecting solar radiation without the need for active cooling systems like air conditioning. Albotherm’s initial focus is on commercial greenhouses, where they demonstrated 34% increase in crop yield compared to other approaches.
Esperto Medical was founded on the principles of making medical care more accessible through automation. Esperto aims to improve medical diagnostics so that clinicians and patients are no longer limited by a hospital environment.
Esperto's first offering is a noninvasive, continuous blood pressure device to enable better vital sign monitoring at home, in the hospital, and maybe even in austere environments. Without an inflating cuff. It's based on first-principles physics: no guessing games, and no finnicky recalibration.
Exciting Instruments is revolutionising single-molecule spectroscopy with a compact, user-friendly EI-FLEX device, designed for high-throughput drug discovery and accessible operation outside traditional lab constraints. An affordable bench-top instrument capable of two-colour, single-molecule fluorescence detection in solution. The EI-FLEX is a versatile tool for studying protein conformations and bimolecular interactions. Now smFRET and FCS experiments are accessible at a benchtop without optical tables or dark rooms.
Oxford Immune Algorithmics is a deep-tech start-up that aims to apply super-human-like Artificial General Intelligence (AGI) to tackle disease and bring decentralised, precise and personalised medicine to everyone. Algocyte is Oxford Immune Algorithmics’s flagship product, a cutting-edge AI-driven solution to monitor people’s health that includes minimally invasive intelligent blood testing and lifestyle data collection. Algocyte combines mechatronics, optics, chemistry, and cell biology with responsible computational intelligence to mimic and enhance human medical reasoning and decision-making in order to create each individual’s health picture.
Harbinger Health is pioneering thttps://www.camilluslife.com/he detection of early cancer and enabling foundationally new approaches to cancer screening, diagnosis and management. The company combines advances in artificial intelligence with proprietary insights into the biology of the beginnings of cancer to identify cancer before it is visible or symptomatic with the aim of developing a low-cost, multi-cancer blood test. Harbinger envisions a future where, instead of keeping cancer from spreading, it could be kept from forming, making a cancer diagnosis a routine health problem to be addressed rather than a life-altering event to be feared with profound implications for people, healthcare systems and societies.
Binding Site provides specialist diagnostic products to clinicians and laboratory professionals worldwide, improving patient lives, delivering innovative medical solutions that improve the diagnosis and management of blood cancers and immune system disorders.
Taking the Pain Out of Blood Collection
YourBio Heath is a medical device company dedicated to improving the blood draw experience. YouBio Health designed and developed Touch Activated Phlebotomy (TAP®), the world’s first push-button blood collection technology that enables TAP® Micro and TAP® Micro Select devices to make the blood sampling process simple, convenient, and virtually painless.